ArticleJCI insight2019
Transmission and clearance of potential procarcinogenic bacteria during fecal microbiota transplantation for recurrent Clostridioides difficile.
Article in JCI insight, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 57 citations in OpenAlex.
- 15-strain live biotherapeutic product or same donor fecal microbiota transplant for recurrent Clostridioides difficile infection: a randomized phase 1b trial.Nature medicine · 2026Trial
- Comparability of Gastrointestinal Microbiome and Bile Acid Profiles in Patients With First or Multiply Recurrent Clostridioides difficile Infection.The Journal of infectious diseases · 2025Trial
- Assessing live microbial therapeutic transmission.Gut microbes · 2025Review
- Review
- Fusobacterium nucleatum and non-coding RNAs: orchestrating oncogenic pathways in colorectal cancer.Gut pathogens · 2025Review
- Memory in Misfire: The Gut Microbiome-Trained Immunity Circuit in Inflammatory Bowel Diseases.International journal of molecular sciences · 2025Review
- Advances in Fecal Microbiota Transplantation for Gut Dysbiosis-Related Diseases.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Pathogen exclusion from intestinal mucus and antimicrobial susceptibility ofMicrobiome research reports · 2025Article
- Article
- Gut microbiota and sepsis-associated encephalopathy: pathogenesis and precision therapies.Frontiers in neuroscience · 2025Review
- Fecal microbiota transplantation: application scenarios, efficacy prediction, and factors impacting donor-recipient interplay.Frontiers in microbiology · 2025Review
- Gut Microecological Prescription: A Novel Approach to Regulating Intestinal Micro-Ecological Balance.International journal of general medicine · 2025Review
- Lower fecal microbiota transplantation ameliorates ulcerative colitis by eliminating oral-derived Fusobacterium nucleatum and virulence factor.Gut pathogens · 2024Article
- Fecal microbiota transplantation: current challenges and future landscapes.Clinical microbiology reviews · 2024Review
- Protective effects of a new generation of probiotic Bacteroides fragilis against colitis in vivo and in vitroScientific reports · 2023Article
- Understanding the mechanisms and translational implications of the microbiome for cancer therapy innovation.Nature cancer · 2023Review
- Article
- Efficacy and Safety of Fecal Microbiota Transplantation in Treatment ofMicroorganisms · 2022Review
- Human gut microbiota stimulate defined innate immune responses that vary from phylum to strain.Cell host & microbe · 2022Article
- Effect of gut microbiota in the colorectal cancer and potential target therapy.Discover oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
BACKGROUNDFecal microbiota transplantation (FMT) is an effective treatment for recurrent Clostridioides difficile infection (rCDI) in adults and children, but donor stool samples are currently screened for only a limited number of potential pathogens. We sought to determine whether putative procarcinogenic bacteria (enterotoxigenic Bacteroides fragilis, Fusobacterium nucleatum, and Escherichia coli harboring the colibactin toxin) could be durably transmitted from donors to patients during FMT.METHODSStool samples were collected from 11 pediatric rCDI patients and their respective FMT donors prior to FMT as well as from the patients at 2-10 weeks, 10-20 weeks, and 6 months after FMT. Bacterial virulence factors in stool DNA extracts and stool cultures were measured by quantitative PCR: Bacteroides fragilis toxin (bft), Fusobacterium adhesin A (fadA), and Escherichia coli colibactin (clbB).RESULTSFour of 11 patients demonstrated sustained acquisition of a procarcinogenic bacteria. Whole genome sequencing was performed on colony isolates from one of these donor/recipient pairs and demonstrated that clbB+ E. coli strains present in the recipient after FMT were identical to a strain present in the donor, confirming strain transmission. Conversely, 2 patients exhibited clearance of procarcinogenic bacteria following FMT from a negative donor.CONCLUSIONBoth durable transmission and clearance of procarcinogenic bacteria occurred following FMT, suggesting that additional studies on appropriate screening measures for FMT donors and the long-term consequences and/or benefits of FMT are warranted.FUNDINGCrohn's & Colitis Foundation, the Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins University School of Medicine, the National Cancer Institute, and the Canadian Institutes of Health Research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.